Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab

• Published in: Osteoarthritis and cartilage Vol. 31; no. 12; pp. 1612 - 1626
• Main Authors: Carrino, John A., McAlindon, Timothy E., Schnitzer, Tom J., Guermazi, Ali, Hochberg, Marc C., Conaghan, Philip G., Brown, Mark T., Burr, Aimee, Fountaine, Robert J., Pixton, Glenn C., Viktrup, Lars, Verburg, Kenneth M., West, Christine R.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.12.2023
• Subjects: Arthroplasty; Kellgren-Lawrence; Nerve growth factor; Radiography; Rapidly progressive osteoarthritis; Radiography; Kellgren-Lawrence; Nerve growth factor; Rapidly progressive osteoarthritis; Arthroplasty
• ISSN: 1063-4584; 1522-9653; 1522-9653
• DOI: 10.1016/j.joca.2023.08.010

Due to the risk of rapidly progressive osteoarthritis (RPOA), the phase III studies of subcutaneous (SC) tanezumab in patients with moderate to severe hip or knee osteoarthritis (OA) included comprehensive joint safety surveillance. This pooled analysis summarizes these findings. Joint safety events in the phase III studies of SC tanezumab (2 placebo- and 1- nonsteroidal anti-inflammatory drug [NSAID]-controlled) were adjudicated by a blinded external committee. Outcomes of RPOA1 and RPOA2, primary osteonecrosis, subchondral insufficiency fracture, and pathological fracture comprised the composite joint safety endpoint (CJSE). Potential patient- and joint-level risk factors for CJSE, RPOA, and total joint replacement (TJR) were explored. Overall, 145/4541 patients (3.2%) had an adjudicated CJSE (0% placebo; 3.2% tanezumab 2.5 mg; 6.2% tanezumab 5 mg; 1.5% NSAID). There was a dose-dependent risk of adjudicated CJSE, RPOA1, and TJR with tanezumab vs NSAID. Patient-level cross-tabulation found associations between adjudicated RPOA with more severe radiographic/symptomatic (joint pain, swelling, and physical limitation) OA. Risk of adjudicated RPOA1 was highest in patients with Kellgren-Lawrence (KL) grade 2 or 3 OA at baseline. Risk of adjudicated RPOA2 or TJR was highest in patients with KL grade 4 joints at baseline. A higher proportion of joints with adjudicated RPOA2 had a TJR (14/26) than those with adjudicated RPOA1 (16/106). In placebo- and NSAID controlled studies of SC tanezumab for OA, adjudicated CJSE, RPOA, and TJR most commonly occurred in patients treated with tanezumab and with more severe radiographic or symptomatic OA. NCT02697773; NCT02709486; NCT02528188